朱栋伟, 赵琪, 柏乐, 潘婷钰, 王晶, 郭申浩, 徐泳, 周贤梅. 麦味养肺汤治疗气阴两虚型特发性肺纤维化的临床疗效[J]. 南京中医药大学学报, 2024, 40(9): 962-969. DOI: 10.14148/j.issn.1672-0482.2024.0962
引用本文: 朱栋伟, 赵琪, 柏乐, 潘婷钰, 王晶, 郭申浩, 徐泳, 周贤梅. 麦味养肺汤治疗气阴两虚型特发性肺纤维化的临床疗效[J]. 南京中医药大学学报, 2024, 40(9): 962-969. DOI: 10.14148/j.issn.1672-0482.2024.0962
shu
ZHU Dongwei, ZHAO Qi, BAI Le, PAN Tingyu, WANG Jing, GUO Shenhao, XU Yong, ZHOU Xianmei. Clinical Efficacy of Maiwei Yangfei Decoction in the Treatment of Idiopathic Pulmonary Fibrosis of Qi-Yin Deficiency Type[J]. Journal of Nanjing University of traditional Chinese Medicine, 2024, 40(9): 962-969. DOI: 10.14148/j.issn.1672-0482.2024.0962
Citation: ZHU Dongwei, ZHAO Qi, BAI Le, PAN Tingyu, WANG Jing, GUO Shenhao, XU Yong, ZHOU Xianmei. Clinical Efficacy of Maiwei Yangfei Decoction in the Treatment of Idiopathic Pulmonary Fibrosis of Qi-Yin Deficiency Type[J]. Journal of Nanjing University of traditional Chinese Medicine, 2024, 40(9): 962-969. DOI: 10.14148/j.issn.1672-0482.2024.0962
shu

麦味养肺汤治疗气阴两虚型特发性肺纤维化的临床疗效

Clinical Efficacy of Maiwei Yangfei Decoction in the Treatment of Idiopathic Pulmonary Fibrosis of Qi-Yin Deficiency Type

    摘要
  • 摘要:
    目的 探讨麦味养肺汤治疗气阴两虚型特发性肺纤维化的治疗作用及安全性。
    方法 选取58例气阴两虚型特发性肺纤维化患者，按1∶1随机分为试验组和对照组各29例，试验组脱落2例，对照组脱落3例。对照组采用西医规范化治疗，试验组在对照组治疗基础上加服麦味养肺汤，2组疗程均为3个月。治疗前后比较2组患者中医证候积分、肺功能、6 min步行距离(6MWD)、经皮血氧饱和度(SpO2)、高分辨率计算机断层扫描(HRCT)评分、圣乔治呼吸问卷(SGRQ)评分和血清涎液化糖链抗原(KL-6)水平变化情况。治疗前后检测2组患者血常规及肝肾功能，记录治疗期间不良反应发生情况。
    结果 治疗后，2组患者中医证候总积分均显著改善(P＜0.01)，试验组优于对照组(P＜0.01)；试验组患者一氧化碳弥散量占预计值百分比(DLCO%)增加(P＜0.05)，试验组高于对照组(P＜0.05)。试验组在6MWD、HRCT网格状影、SGRQ症状评分、总评分及血清KL-6水平均显著改善(P＜0.05，P＜0.01)，优于对照组(P＜0.05，P＜0.01)。治疗期间2组均未见严重不良事件发生。
    结论 麦味养肺汤联合西医规范化治疗可有效改善气阴两虚型特发性肺纤维化患者临床症状，降低血清KL-6表达水平，疗效确切，且安全性好。

     

    Abstract:
    OBJECTIVE To explore the therapeutic effect and safety of Maiwei Yangfei Decoction (MWYF) in the treatment of idiopathic pulmonary fibrosis of qi-yin deficiency type.
    METHODS A total of 58 patients with idiopathic pulmonary fibrosis of qi-yin deficiency type were randomly divided into an experimental group and a control group with 29 cases in each group according to a 1:1 ratio. Two cases dropped out of the experimental group and three cases dropped out of the control group. The control group received standardized treatment of Western medicine, and the experimental group received MWYF on the basis of the treatment of the control group. The treatment course of both groups was 3 months. The TCM syndrome score, lung function, 6-minute walking distance (6MWD), transcutaneous blood oxygen saturation (SpO2), high-resolution computed tomography (HRCT) score, St. George's respiratory questionnaire (SGRQ) score and serum sialoglycoprotein antigen (KL-6) level of the two groups were compared before and after treatment. Blood routine and liver and kidney function of the two groups were detected before and after treatment, and the occurrence of adverse reactions during treatment was recorded.
    RESULTS After treatment, the total score of TCM syndrome of the two groups was significantly improved (P < 0.01), and the experimental group was better than the control group (P < 0.01); the DLCO% of the experimental group increased (P < 0.05), and the experimental group was higher than the control group (P < 0.05). The experimental group showed significant improvement in 6MWD, HRCT grid shadow, SGRQ symptom score and total score, and serum KL-6 level (P < 0.05, P < 0.01), which was better than the control group (P < 0.05, P < 0.01). No serious adverse events occurred in either group during the treatment.
    CONCLUSION MWYF combined with standardized Western medicine treatment can effectively improve the clinical symptoms of patients with idiopathic pulmonary fibrosis of qi-yin deficiency type, reduce the expression level of serum KL-6, and has a definite effect and good safety.

     

    • HTML全文
    • 参考文献(38)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回